{"id":"nimesulide-pantoprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL56367","moleculeType":"Small molecule","molecularWeight":"308.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination where nimesulide, a selective COX-2 inhibitor NSAID, provides anti-inflammatory and analgesic effects by blocking prostaglandin synthesis. Pantoprazole, a proton pump inhibitor, reduces gastric acid secretion to mitigate NSAID-induced gastrointestinal toxicity and ulceration risk. The combination allows therapeutic NSAID dosing with reduced GI adverse effects.","oneSentence":"Nimesulide inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain, while pantoprazole suppresses gastric acid production to protect the stomach lining.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:03.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain and inflammation with gastric protection"},{"name":"Musculoskeletal pain conditions requiring NSAID therapy with reduced GI risk"}]},"trialDetails":[{"nctId":"NCT01670552","phase":"PHASE3","title":"Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients","status":"COMPLETED","sponsor":"EMS","startDate":"2016-02-17","conditions":"Acute and Chronic Inflammation, Dyspepsia","enrollment":490}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nimesulide + Pantoprazole","genericName":"Nimesulide + Pantoprazole","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimesulide, a small molecule, and Pantoprazole have been studied together for the treatment of acute and chronic inflammation, as well as dyspepsia, in clinical trials. The combination of Nimesulide and Pantoprazole has been evaluated for safety in a parallel, double-blind, randomized study for the treatment of osteoarticular inflammation in dyspeptic patients.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}